Survival rates of children and young adolescents with CNS tumors improved in the Netherlands since 1990: A population-based study

Abstract Introduction Survival of children with central nervous system (CNS) tumors varies largely between countries. For the Netherlands, detailed population-based estimation of incidence, survival and mortality of pediatric CNS tumors are lacking but are needed to evaluate progress. Methods All CNS tumors diagnosed in patients <18 years during 1990-2017 were selected from the Netherlands Cancer Registry. Other than pilocytic astrocytomas, non-malignant tumors were included since 2000. Incidence and mortality trends were evaluated by Average Annual Percentage Change (AAPC). Changes over time in Five-year Observed Survival (5-year OS) were evaluated by Poisson regression models adjusted for follow-up time. Results Between 1990 and 2017, 2057 children were diagnosed with a malignant CNS tumor and 885 with a pilocytic astrocytoma. During 2000-17, 695 children were diagnosed with other non-malignant CNS tumors. Incidence rates of malignant tumors remained stable, while pilocytic astrocytomas and other non-malignant tumors increased by 2.0% and 2.4% per year, respectively. 5-year OS rates improved for all groups; however, improvement for malignant tumors was not constant over time. The contribution of malignant tumors located at the optic nerve tumors was 1% in 2000-09. However, shifting from pilocytic astrocytomas, increased to 6% in 2010-17, impacting survival outcomes for malignant tumors. Conclusion Survival rates of CNS tumors improved over time, but was not accompanied by a decreasing mortality rate. The observed temporary survival deterioration for malignant tumors appears to be related to changes in diagnostics and registration practices. Whether differences in treatment regimens contribute to this temporary decline in survival needs to be verified.

Download Full-text

Incidence, Survival, and Mortality Trends of Cancers Diagnosed in Adolescents and Young Adults (15–39 Years): A Population-Based Study in The Netherlands 1990–2016

Cancers ◽

10.3390/cancers12113421 ◽

2020 ◽

Vol 12 (11) ◽

pp. 3421

Author(s):

Daniël J. van der Meer ◽

Henrike E. Karim-Kos ◽

Marianne van der Mark ◽

Katja K. H. Aben ◽

Rhodé M. Bijlsma ◽

...

Keyword(s):

The Netherlands ◽

Cancer Patients ◽

Cancer Incidence ◽

Relative Survival ◽

Mortality Rates ◽

Adolescent And Young Adult ◽

Mortality Trends ◽

Netherlands Cancer Registry ◽

Incidence And Mortality ◽

Cancer Types

Adolescent and young adult (AYA) cancer patients, aged 15–39 years at primary cancer diagnosis, form a distinct, understudied, and underserved group in cancer care. This study aimed to assess long-term trends in incidence, survival, and mortality of AYA cancer patients within the Netherlands. Data on all malignant AYA tumours diagnosed between 1990–2016 (n = 95,228) were obtained from the Netherlands Cancer Registry. European age-standardised incidence and mortality rates with average annual percentage change (AAPC) statistics and five-year relative survival rates were calculated. The overall cancer incidence increased from 54.6 to 70.3 per 100,000 person-years (AAPC: +1.37%) between 1990–2016, and increased for both sexes individually and for most cancer types. Five-year relative survival overall improved from 73.7% in 1990–1999 to 86.4% in 2010–2016 and improved for both sexes and most cancer types. Survival remained poor (<60%) for rhabdomyosarcoma, lung, stomach, liver, bladder, and pancreatic carcinomas, among others. Mortality rates among male AYAs overall declined from 10.8 to 6.6 (AAPC: −1.64%) and from 14.4 to 10.1 per 100,000 person-years (AAPC: −1.81%) for female AYAs since 1990. Mortality rates remained unchanged for male AYAs aged 20–24 and 25–29 years. In conclusion, over the past three decades, there has been a considerable increase in cancer incidence among AYAs in the Netherlands. Meanwhile, the survival improved and the mortality overall declined. Survival at five-years now well exceeds above 80%, but did not do so for all cancer types.

Download Full-text

EPID-18. TRENDS IN INCIDENCE AND SURVIVAL OF MALIGNANT PEDIATRIC CENTRAL NERVOUS SYSTEM TUMORS IN THE NETHERLANDS

Neuro-Oncology ◽

10.1093/neuonc/noaa222.204 ◽

2020 ◽

Vol 22 (Supplement_3) ◽

pp. iii322-iii322

Author(s):

Raoull Hoogendijk ◽

Jasper van der Lugt ◽

Dannis van Vuurden ◽

Eelco Hoving ◽

Leontien Kremer ◽

...

Keyword(s):

Central Nervous System ◽

Nervous System ◽

The Netherlands ◽

Malignant Gliomas ◽

Survival Rates ◽

Tumor Patients ◽

Netherlands Cancer Registry ◽

Malignant Astrocytomas ◽

Brainstem Tumors ◽

The Impact

Abstract BACKGROUND Variation in survival of pediatric central nervous system (CNS) tumors is large between countries. Within Europe, the Netherlands had one of the worst reported survival rates of malignant CNS (mCNS) tumors during 2000–2007. METHODS Using the Netherlands Cancer Registry, we evaluated trends in incidence and survival of pediatric mCNS tumors (behavior /3, 5th digit in the morphology code) diagnosed between 1990–2017. RESULTS 839 newly-diagnosed mCNS tumor patients <18 years were registered between 1990–2017. Incidence of mCNS tumors remained stable (average incidence rate, 21.6 per million person-years). However, an increased incidence of malignant gliomas, NOS was found (Estimated Annual Percentage Change (EAPC) 11.6% p<0.001). This appears to be related to a registration shift between 1990–1999 and 2000–2009 as brainstem tumors increased (+25%, n=79) for astrocytomas and other gliomas but decreased (-31%, n=32) for unspecified intracranial and intraspinal neoplasms. Overall, 5-year observed survival (5Y-OS) of mCNS tumors increased from 51% in 1990–1999 to 61% in 2010–2017 (P-for-trend<0.001). This increase was not constant over time, as 5Y-OS for the period 2000–2009 was 47%. The only significant decrease in survival was found for malignant astrocytomas and other gliomas with a 5Y-OS of 56% in 1990–1999 decreasing to 48% in 2010–2017 (P-for-trend<0.001). CONCLUSION Between 1990–2017 incidence of mCNS tumors in the Netherlands remained stable and survival increased. However, a decrease in survival was seen for malignant astrocytomas and other gliomas, which is partially explained by the registration shift of brainstem tumors. The impact of this shift on survival for all mCNS tumors is subject to further research.

Download Full-text

Time trends in treatment strategies and survival of older versus younger patients with synchronous metastasized melanoma – a population-based study in the Netherlands Cancer Registry

Journal of Geriatric Oncology ◽

10.1016/s1879-4068(21)00336-2 ◽

2021 ◽

Vol 12 (8) ◽

pp. S5

Author(s):

D. van der Ziel ◽

M. Derks ◽

E. Kapiteijn ◽

E. Bastiaannet ◽

M. Louwman ◽

...

Keyword(s):

The Netherlands ◽

Cancer Registry ◽

Time Trends ◽

Treatment Strategies ◽

Population Based ◽

Population Based Study ◽

Younger Patients ◽

Netherlands Cancer Registry

Download Full-text

Trender i insidens og mortalitet av kreft i Norge

Norsk Epidemiologi ◽

10.5324/nje.v11i2.554 ◽

2009 ◽

Vol 11 (2) ◽

Author(s):

Steinar Tretli ◽

Trude Eid Robsahm ◽

Elisabeth Svensson

Keyword(s):

Case Fatality ◽

English Summary ◽

Classification Rules ◽

Font Size ◽

Treatment Results ◽

Mortality Trends ◽

Calendar Time ◽

Incidence And Mortality ◽

Short Time ◽

Over Time

ENGLISH SUMMARYTretli S, Robsahm TE, Svensson E. Time trends in cancer incidence and mortality in Norway.Nor J Epidemiol 2001; 11 (2): 177-185.The aim of this study is to decribe the trends in incidence and mortality of cancer by calendar time.Most types of cancer, except those with high case fatality short time after the diagnosis, demonstrate alarger increase in incidence than in mortality over time. For persons below 70 years of age during theperiod 1931-95 the mortality rate has been close to constant. Obviously, the mortality of lung andstomach cancer has changed over time, however, these have changed in different direction and almostlevelled out. In this paper, it is discussed how registration routines, classification rules, treatment resultsand the basis of the diagnosis can influence the incidence and mortality trends.

Download Full-text

Time Trends and Prognostic Factors for Overall Survival in Myxoid Liposarcomas: A Population-Based Study

Sarcoma ◽

10.1155/2020/2437850 ◽

2020 ◽

Vol 2020 ◽

pp. 1-8

Author(s):

Jules Lansu ◽

Winan J. Van Houdt ◽

Michael Schaapveld ◽

Iris Walraven ◽

Michiel A. J. Van de Sande ◽

...

Keyword(s):

Overall Survival ◽

Prognostic Factors ◽

The Netherlands ◽

Metastatic Disease ◽

Lower Limb ◽

Tumor Size ◽

Tumor Location ◽

Population Based ◽

Population Based Study ◽

Over Time

Background. The purpose of this study was to evaluate the overall survival (OS) and associated characteristics for patients with Myxoid Liposarcoma (MLS) over time in The Netherlands. Methods. A population-based study was performed of patients with primary localized (n = 851) and metastatic (n = 50) MLS diagnosed in The Netherlands between 1989 and 2016, based on data from the National Cancer Registry. Results. The median age of the MLS patients was 49 years, and approximately two-thirds was located in the lower limb. An association was revealed between age and the risk of having a Round Cell (RC) tumor. OS rates for primary localized MLS were 93%, 83%, 78%, and 66% after 1, 3, 5, and 10 years, respectively. The median OS for patients with metastatic disease at diagnosis was 10 months. Increasing age (Hazard Ratio (HR) 1.05, p=0.00), a tumor size >5 cm (HR 2.18; p=0.00), and tumor location (trunk HR 1.29; p=0.09, upper limb HR 0.83; p=0.55, and “other” locations HR 2.73; p=0.00, as compared to lower limb) were independent prognostic factors for OS. The percentage of patients treated with radiotherapy (RT) increased over time, and preoperative RT gradually replaced postoperative RT. In contrast to patients with localized disease, significant improvement of OS was observed in patients with metastatic disease over time. Conclusions. In this large nationwide cohort, tumor size and tumor location were independent prognostic factors for OS. Furthermore, a higher probability of an RC tumor with increasing age was suggested. An increased use of RT over the years did not translate into improved OS for localized MLS.

Download Full-text

Incidence, Mortality, and Spatiotemporal Distribution of Cutaneous Malignant Melanoma Cases Across Canada

Journal of Cutaneous Medicine and Surgery ◽

10.1177/1203475419852048 ◽

2019 ◽

Vol 23 (4) ◽

pp. 394-412 ◽

Cited By ~ 7

Author(s):

Feras M. Ghazawi ◽

Michelle Le ◽

François Lagacé ◽

Janelle Cyr ◽

Nebras Alghazawi ◽

...

Keyword(s):

Malignant Melanoma ◽

Age Groups ◽

Population Based ◽

Geographic Region ◽

Cutaneous Malignant Melanoma ◽

Steady Increase ◽

Mortality Trends ◽

Incidence And Mortality ◽

Future Burden ◽

Melanoma Mortality

Background: We recently reported a steady increase in the incidence and mortality of cutaneous malignant melanoma (CMM) in Canada during 1992-2010. Objectives: The objective of this article is to examine the distribution of Canadian CMM patients at the level of provinces, cities, and forward sortation area (FSA) postal codes. Methods: Using 3 Canadian population-based registries, we conducted an in-depth examination of the incidence and mortality trends for 72 565 Canadian CMM patients over the period 1992-2010. Results: We found that among 20- to 39-year-olds, the incidence of CMM in women (7.17 per 100 000 individuals) was significantly higher than in men (4.60 per 100 000 individuals per year). Women age 80 years and older had an incidence of CMM (58.46 cases per 100 000 women per year) more than 4 times greater than the national average (12.29 cases per 100 000 population per year) and a corresponding high mortality rate (20.18 deaths per 100 000 women per year), when compared with the Canadian melanoma mortality of 2.4 deaths per 100 000 per year. In other age groups men had higher incidence and corresponding melanoma mortality rates. We also studied CMM incidence by province, city, and FSA postal codes and identified several high-incidence communities that were located near the coast/waterfronts. In addition, plotting latitude measures for cities and FSAs vs CMM incidence rate confirmed the inverse relationship between geographical latitude and incidence of melanoma in Canada (slope = –0.22 ± 0.05). Conclusions: This research may help develop sex-, age- and geographic region-specific recommendations to decrease the future burden of CMM in Canada.

Download Full-text

Trends in Overall Survival and Treatment Patterns in Two Large Population-Based Cohorts of Patients with Breast and Colorectal Cancer

Cancers ◽

10.3390/cancers11091239 ◽

2019 ◽

Vol 11 (9) ◽

pp. 1239 ◽

Cited By ~ 1

Author(s):

Abbema ◽

Vissers ◽

Vos-Geelen ◽

Lemmens ◽

Janssen-Heijnen ◽

...

Keyword(s):

Colorectal Cancer ◽

Overall Survival ◽

Survival Rates ◽

Relative Survival ◽

Population Based ◽

Treatment Patterns ◽

Entire Study ◽

Younger Patients ◽

Risk Of Death ◽

Over Time

Previous studies showed substantial improvement of survival rates in patients with cancer in the last two decades. However, lower survival rates have been reported for older patients compared to younger patients. In this population-based study, we analyzed treatment patterns and the survival of patients with breast cancer (BC) and colorectal cancer (CRC). Patients with stages I–III BC and CRC and diagnosed between 2003 and 2012 were selected from the Netherlands Cancer Registry (NCR). Trends in treatment modalities were evaluated with the Cochran-Armitage trend test. Trends in five-year overall survival were calculated with the Cox hazard regression model. The Ederer II method was used to calculate the five-year relative survival. The relative excess risk of death (RER) was estimated using a multivariate generalized linear model. During the study period, 98% of BC patients aged <75 years underwent surgery, whereas for patients ≥75 years, rates were 79.3% in 2003 and 66.7% in 2012 (p < 0.001). Most CRC patients underwent surgery irrespective of age or time period, although patients with rectal cancer aged ≥75 years received less surgery or radiotherapy over the entire study period than younger patients. The administration of adjuvant chemotherapy increased over time for CRC and BC patients, except for BC patients aged ≥75 years. The five-year relative survival improved only in younger BC patients (adjusted RER 0.95–0.96 per year), and was lower for older BC patients (adjusted RER 1.00, 95% Confidence Interval (CI) 0.98–1.02, and RER 1.00; 95% CI 0.98–1.01 per year for 65–74 years and ≥75 years, respectively). For CRC patients, the five-year relative survival improved over time for all ages (adjusted RER on average was 0.95 per year). In conclusion, the observed survival trends in BC and CRC patients suggest advances in cancer treatment, but with striking differences in survival between older and younger patients, particularly for BC patients.

Download Full-text

A population-based study of the incidence and survival rates in patients with pilocytic astrocytoma

Journal of Neurosurgery ◽

10.3171/jns.2003.98.6.1170 ◽

2003 ◽

Vol 98 (6) ◽

pp. 1170-1174 ◽

Cited By ~ 143

Author(s):

Christoph Burkhard ◽

Pier-Luigi Di Patre ◽

Danielle Schüler ◽

Georges Schüler ◽

M. Gazi Yaşargil ◽

...

Keyword(s):

Pilocytic Astrocytoma ◽

Postoperative Radiotherapy ◽

Survival Rates ◽

Population Based ◽

Biological Behavior ◽

Population Based Study ◽

Content Type ◽

Pilocytic Astrocytomas ◽

The Mean ◽

Fine Print

Object. The incidence of pilocytic astrocytomas and the rate of patient survival were analyzed in a population-based study in the canton of Zürich, Switzerland. Methods. Between 1980 and 1994, 987 astrocytic and oligodendroglial tumors were diagnosed, of which 55 (5.5%) were pilocytic astrocytomas. The incidence rate, adjusted to the World Standard Population, was 4.8 per 1 million per year. The mean age at clinical diagnosis was 19.6 ± 12.7 years, and the male/female ratio was 1.12. The most frequent tumor sites were the cerebellum (40%), followed by supratentorial locations (35%), the optic pathway and hypothalamus (11%), and the brainstem (9%). The mean follow-up period was 12 years. Observed survival rates were 100% at 5 years and 95.8% at 10 years after diagnosis (relative survival rate at 10 years: 96.8%). Seven patients (13%) received postoperative radiotherapy, but this did not significantly affect survival. In all patients the tumors were histologically classified as WHO Grade I, except in two patients who had anaplastic pilocytic astrocytoma (Grade III), one of whom died after 7 years, whereas the other was still alive after 10 years. Conclusions. This population-based study shows that, because of the benign biological behavior of pilocytic astrocytomas and advances in microneurosurgery, the survival rates for patients with these tumors are excellent, regardless of postoperative radiotherapy.

Download Full-text

Surgery for adrenocortical carcinoma in The Netherlands: analysis of the national cancer registry data

Acta Endocrinologica ◽

10.1530/eje-13-0142 ◽

2013 ◽

Vol 169 (1) ◽

pp. 83-89 ◽

Cited By ~ 31

Author(s):

T M A Kerkhofs ◽

R H A Verhoeven ◽

H J Bonjer ◽

E J Nieveen van Dijkum ◽

M R Vriens ◽

...

Keyword(s):

The Netherlands ◽

Cancer Registry ◽

Adrenocortical Carcinoma ◽

Survival Benefit ◽

Locally Advanced ◽

Improve Patient Care ◽

Population Based ◽

Adrenal Tumors ◽

Cancer Registry Data ◽

Netherlands Cancer Registry

ObjectiveAdrenocortical carcinoma (ACC) is a rare disease with an estimated incidence of one to two cases per 1 million inhabitants. The Dutch Adrenal Network (DAN) was initiated with the aim to improve patient care and to stimulate scientific research on ACC. Currently, not all patients with ACC are treated in specialized DAN hospitals. The objective of the current investigation was to determine whether there are differences in survival between patients operated on in DAN hospitals and those operated on in non-DAN hospitals.DesignThe study was set up as a retrospective and population-based survival analysis.MethodsData on all adult ACC patients diagnosed between 1999 and 2009 were obtained from The Netherlands Cancer Registry (NCR). Overall survival was calculated and a comparison was made between DAN and non-DAN hospitals.ResultsThe NCR contained data of 189 patients. The median survival of patients with European Network for the Study of Adrenal Tumors stages I–III disease was significantly longer for patients operated on in a DAN hospital (n=46) than for those operated on in a non-DAN hospital (n=37, 5-year survival 63 vs 42%). Survival remained significantly different after correction for sex, age, year of diagnosis, and stage of disease in the multivariate analysis (hazard ratio 1.96 (95% CI 1.01–3.81), P=0.047).ConclusionThe results associate surgery in a DAN center with a survival benefit for patients with local or locally advanced ACC. We hypothesize that a multidisciplinary approach for these patients explains the observed survival benefit. These findings should be carefully considered in view of the aim for further centralization of ACC treatment.

Download Full-text

Rising incidence, no change in survival and decreasing mortality from thyroid cancer in The Netherlands since 1989

Endocrine Related Cancer ◽

10.1530/erc-12-0336 ◽

2013 ◽

Vol 20 (2) ◽

pp. 263-271 ◽

Cited By ~ 32

Author(s):

Olga Husson ◽

Harm R Haak ◽

Liza N van Steenbergen ◽

Willy-Anne Nieuwlaat ◽

Boukje A C van Dijk ◽

...

Keyword(s):

Thyroid Cancer ◽

The Netherlands ◽

Survival Rates ◽

Age Groups ◽

Relative Survival ◽

Incidence Rates ◽

Mortality Data ◽

Netherlands Cancer Registry ◽

Rising Incidence ◽

Tumour Node

The incidence of thyroid cancer (TC) is increasing worldwide, partly due to increased detection. We therefore assessed combined trends in incidence, survival and mortality of the various types of TC in The Netherlands between 1989 and 2009. We included all patients ≥15 years with TC, diagnosed in the period 1989–2009 and recorded in The Netherlands Cancer Registry (n=8021). Information on age, gender, date of diagnosis, histological type of tumour and tumour–node–metastasis classification was recorded. Mortality data (up to 1st January 2010) were derived from Statistics Netherlands. Annual percentages of change in incidence, mortality and relative survival were calculated. Since 1989 the incidence of TC increased significantly in The Netherlands (estimated annual percentage change (EAPC)=+1.7%). The incidence rates increased for all age groups (except for females >60 years), papillary tumours (EAPC=+3.5%), T1 and T3 TC (EAPC=+7.9 and +5.8% respectively). Incidence rates decreased for T4 TC (−2.3%) and remained stable for follicular, medullary anaplastic and T2 TC. Five-year relative survival rates remained stable for papillary (88%) and follicular (77%) TC, all age groups and T1–T3 TC (96, 94 and 80% respectively) and somewhat lower for T4 (53%), medullary (65%) and anaplastic TC (5%) in the 2004–2009 period compared with earlier periods. Mortality due to TC decreased (EAPC=−1.9%). TC detection and incidence has been rising in The Netherlands, while mortality rates are decreasing and survival rates remained stable or slightly decreasing.

Download Full-text